Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 126, Issue 1, Pages 215-220Publisher
SPRINGER
DOI: 10.1007/s10549-010-1224-1
Keywords
Breast cancer; Metformin; Adjuvant; Clinical testing
Categories
Ask authors/readers for more resources
Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available